Pharmaceutical Executive
FTC is looking to ban reverse-payment settlements and pharma must tread with caution.
Pharmaceutical Executive-01-24-2007
Pharmaceutical Executive
Experts offer strategies for blocking repeal of non-interference bill.
Pharmaceutical Executive
Kindler's Strategic Direction Is Neither, Say Cranky Analysts
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
